Fortress Biotech, Inc. Contracts & Agreements

Form of Placement Agency Agreement, dated November 10, 2023, by and between the Company and Roth Capital Partners, LLC (Filed With SEC on November 14, 2023)

Form of Securities Purchase Agreement, dated November 10, 2023, by and among the Company and the purchasers party thereto (Filed With SEC on November 14, 2023)

Form of Warrant (Filed With SEC on November 14, 2023)

Amendment to the Fortress Biotech, Inc. 2013 Stock Incentive Plan (Filed With SEC on June 23, 2023)

Amendment to the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan (Filed With SEC on June 23, 2023)

Form of Amended and Restated Warrant (Filed With SEC on June 16, 2023)

Description of Securities of Fortress Biotech, Inc (Filed With SEC on March 31, 2023)

Form of Contingent Subsidiary Security (Filed With SEC on February 9, 2023)

Form of Securities Purchase Agreement, dated February 7, 2023, by and among the Company and the purchasers party thereto (Filed With SEC on February 9, 2023)

Form of Side Letter, dated February 7, 2023, by and among the Company and the purchasers party thereto (Filed With SEC on February 9, 2023)

Form of Indemnification Agreement (Lucy Lu) (Filed With SEC on December 19, 2022)

Form of Restricted Stock Unit Agreement (David Jin) (Filed With SEC on October 28, 2022)

Amendment to the Fortress Biotech, Inc. 2013 Stock Incentive Plan (Filed With SEC on June 27, 2022)

Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on August 27, 2020 (Filed With SEC on August 16, 2021)

Asset Purchase Agreement entered into by and between Sentynl Therapeutics, Inc. and Cyprium Therapeutics, Inc. dated as of February 23, 2021 (Filed With SEC on August 16, 2021)

Asset Purchase Agreement entered into by and between Journey Medical Corporation and Dermira, Inc. dated as of March 31, 2021 (Filed With SEC on August 16, 2021)

Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on August 27, 2020 (Filed With SEC on May 17, 2021)

Asset Purchase Agreement entered into by and between Sentynl Therapeutics, Inc. and Cyprium Therapeutics, Inc. dated as of February 23, 2021 (Filed With SEC on May 17, 2021)

Asset Purchase Agreement entered into by and between Journey Medical Corporation and Dermira, Inc. dated as of March 31, 2021 (Filed With SEC on May 17, 2021)

Description of Securities of Fortress Biotech, Inc (Filed With SEC on March 31, 2021)

Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on August 27, 2020 (Filed With SEC on November 9, 2020)

Underwriting Agreement, dated August 26, 2020, by and among Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, Inc (Filed With SEC on August 28, 2020)

Amendment to the Fortress Biotech, Inc. 2013 Stock Incentive Plan (Filed With SEC on June 19, 2020)

At Market Issuance Sales Agreement between the Company and Cantor Fitzgerald & Co., Oppenheimer & Co. Inc., H.C. Wainwright & Co., LLC, B. Riley FBR, Inc., and Dawson James... (Filed With SEC on May 29, 2020)

Underwriting Agreement, dated May 26, 2020, by and among Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, Inc (Filed With SEC on May 28, 2020)

Description of Securities of Fortress Biotech, Inc (Filed With SEC on March 16, 2020)

Underwriting Agreement, dated February 11, 2020, between Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, as... (Filed With SEC on February 12, 2020)

Underwriting Agreement, dated November 25, 2019, between Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, as... (Filed With SEC on November 26, 2019)

Development, Option and Stock Purchase Agreement dated January 30, 2019 by and among Fortress Biotech, Inc., Caelum Biosciences, Inc. (Caelum), Alexion Therapeutics, Inc., and the... (Filed With SEC on May 10, 2019)

Amended and Restated Consulting Agreement, entered into as of January 1, 2019, by and between the Registrant and Eric Rowinsky (Filed With SEC on March 18, 2019)

Stock Purchase Agreement by and among FBIO Acquisition, Inc., Fortress Biotech, Inc., and NHC Holdings, LLC, dated November 14, 2018 (Filed With SEC on November 20, 2018)

Restrictive Covenant Agreement, dated as of November 12, 2018, by and between Fortress Biotech, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 16, 2018)

Stock Purchase and Merger Agreement, dated as of November 12, 2018, by and between Avenue Therapeutics, Inc., InvaGen Pharmaceuticals Inc. and Madison Pharmaceuticals Inc (Filed With SEC on November 16, 2018)

Stockholders Agreement, dated as of November 12, 2018, by and between Fortress Biotech, Inc., Avenue Therapeutics, Inc., Dr. Lucy Lu, M.D. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 16, 2018)

Credit Agreement, dated as of November 12, 2018, by and between Avenue Therapeutics, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 16, 2018)

Guaranty, dated as of November 12, 2018, by and between Fortress Biotech, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 16, 2018)

Waiver Agreement, dated as of November 12, 2018, by and between Fortress Biotech, Inc., Avenue Therapeutics, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 16, 2018)

Indemnification Agreement, dated as of November 12, 2018, by and between Fortress Biotech, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 16, 2018)

Voting and Support Agreement, dated as of November 12, 2018, by and between Fortress Biotech, Inc., Avenue Therapeutics, Inc., Dr. Lucy Lu, M.D. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 16, 2018)

At Market Issuance Sales Agreement, among the Company and B. Riley FBR, Inc., National Securities Corporation, LifeSci Capital LLC, Maxim Group LLC and Noble Capital Markets, Inc.... (Filed With SEC on April 5, 2018)

Amended and Restated Credit Facility Agreement dated as of March 12, 2018, by and among Fortress Biotech, Inc. and Opus Point Healthcare Innovations Fund, L.P (Filed With SEC on March 16, 2018)

Underwriting Agreement, dated November 6, 2017, between Fortress Biotech, Inc. and B. Riley FBR, Inc., as representative of the several underwriters named therein (Filed With SEC on November 7, 2017)

FORM OF FORTRESS BIOTECH,INC. PROMISSORY NOTE (Filed With SEC on May 10, 2017)

FORM OF NOTE PURCHASEAGREEMENT (Filed With SEC on May 10, 2017)

FORM OF COMMON STOCK PURCHASEWARRANT To Purchase [_____] Shares of Common Stockof Fortress Biotech, Inc. (Filed With SEC on May 10, 2017)

NATIONAL SECURITIES ESTABLISHED 1947 (Filed With SEC on May 10, 2017)

NATIONAL SECURITIES ESTABLISHED1947 (Filed With SEC on May 10, 2017)

FORM OFCOMMON STOCK PURCHASE WARRANT To Purchase [___________] Sharesof Common Stock of Fortress Biotech, Inc. (Filed With SEC on November 9, 2016)

CREDIT FACILITY AGREEMENT (Filed With SEC on November 9, 2016)

Form of Fortress Biotech, Inc. CONVERTIBLE SECUREDPROMISSORY NOTE (Filed With SEC on November 9, 2016)

PLEDGE AND SECURITY AGREEMENT (Filed With SEC on November 9, 2016)

FORTRESS BIOTECH, INC. Common Stock (par value $0.001 per share) Amended and Restated At Market IssuanceSales Agreement (Filed With SEC on August 17, 2016)

AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (Filed With SEC on August 12, 2016)

AMENDMENT NO.2 TO At market issuance SALES AGREEMENT (Filed With SEC on May 4, 2016)

AGREEMENTAND PLAN OF MERGER By and Among NATIONAL HOLDINGSCORPORATION, FORTRESSBIOTECH, INC. and FBIO ACQUISITION,INC. Dated as ofApril 27, 2016 (Filed With SEC on April 28, 2016)

FORM OF SUPPORT AND VOTING AGREEMENT (Filed With SEC on April 28, 2016)

STOCKHOLDER RIGHTS AGREEMENT (Filed With SEC on April 28, 2016)

FORM OF VOTING AGREEMENT (Filed With SEC on April 28, 2016)

FORTRESS BIOTECH, INC. Amendedand Restated Promissory Note (Filed With SEC on August 4, 2015)

FORTRESS BIOTECH, INC. 2013 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on July 17, 2015)

CORONADO BIOSCIENCES INC. Deferredcompensation plan for directors (Filed With SEC on March 18, 2015)

[___________], INC. PromissoryNote (Filed With SEC on March 5, 2015)

NOTE PURCHASEAGREEMENT (Filed With SEC on March 5, 2015)

FORM OF SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 5, 2015)

[SUBCO] COMMON STOCK WARRANT (Filed With SEC on March 5, 2015)

CORONADO BIOSCIENCES, INC. PromissoryNote (Filed With SEC on March 5, 2015)

NAME OF SUBSCRIBER: _________________ CORONADO BIOSCIENCES, INC. SUBSCRIPTIONAGREEMENT (Filed With SEC on November 10, 2014)

Coronado Biosciences Inc. RESTRICTED STOCK ISSUANCE AGREEMENT (Filed With SEC on March 14, 2014)

CONFIDENTIAL SEPARATION AND RELEASEAGREEMENT (Filed With SEC on March 14, 2014)

Coronado Biosciences Inc. RESTRICTED STOCK ISSUANCE AGREEMENT (Filed With SEC on February 26, 2014)

SHAREHOLDERS’ AGREEMENT (Filed With SEC on February 26, 2014)

ASSIGNMENT AND PLEDGE OF MONEY MARKETACCOUNT (Filed With SEC on February 18, 2014)

PROMISSORY NOTE (Filed With SEC on February 18, 2014)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on November 6, 2013)

AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on August 5, 2013)

CORONADO BIOSCIENCES, INC. 2013 STOCK INCENTIVE PLAN (Filed With SEC on June 21, 2013)

LICENSE AND SUBLICENSE AGREEMENT (Filed With SEC on May 9, 2013)

RESEARCH AGREEMENT (Filed With SEC on May 9, 2013)

CORONADO BIOSCIENCES, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement (Filed With SEC on April 29, 2013)

Portions of this exhibit marked [*] are requested to be treated confidentially. (Filed With SEC on March 18, 2013)

SEPARATION AND RELEASE AGREEMENT (Filed With SEC on March 18, 2013)

SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on March 18, 2013)

EMPLOYMENT AGREEMENT (Filed With SEC on March 18, 2013)

Portions of this exhibit marked [ * ] are requested to be treated confidentially. CUMMINGS PROPERTIES, LLC (Filed With SEC on March 18, 2013)

CORONADO BIOSCIENCES, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement (Filed With SEC on October 5, 2012)

WARRANT AGREEMENT To Purchase Shares of the Common Stock of Coronado Biosciences, Inc. Dated as of August 28, 2012 (the Effective Date) (Filed With SEC on August 29, 2012)

LOAN AND SECURITY AGREEMENT (Filed With SEC on August 29, 2012)

5,000,000 Shares CORONADO BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on June 26, 2012)

4,600,000 Shares CORONADO BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on June 21, 2012)

2,000,000 Shares CORONADO BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on June 12, 2012)

CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIALTREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH [*******] OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED... (Filed With SEC on May 25, 2012)

CORONADO BIOSCIENCES, INC. EMPLOYMENT AGREEMENT (Filed With SEC on April 25, 2012)

CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIALTREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH [*******] OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED... (Filed With SEC on March 23, 2012)

CORONADO BIOSCIENCES, INC. EMPLOYMENT AGREEMENT (Filed With SEC on February 23, 2012)

TERMS OF AGREEMENT (Filed With SEC on December 22, 2011)

AMENDMENT NO. 1 TO AGREEMENT (Filed With SEC on December 22, 2011)

SIDE AGREEMENT (Filed With SEC on December 22, 2011)

CORONADO BIOSCIENCES, INC. CONSULTINGAGREEMENT (Filed With SEC on October 7, 2011)

CORONADO BIOSCIENCES, INC. EMPLOYMENT AGREEMENT (Filed With SEC on September 26, 2011)